Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Face

NCT01720407 is registered in ClinicalTrials.gov with Nantes University Hospital as lead sponsor.

NCT NCT01720407
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01720407 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Face
Lead sponsor
Nantes University Hospital
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2012
Completion date
November 10, 2022
Enrollment
259 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

lentigo maligna melanoma (head or neck)